Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 4/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16493550 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL5907428 | 0.79 | FAAH (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2783090 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25868 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2782415 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466673 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466582 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466941 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466752 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| Phosphoric Acid SCHEMBL5312301 | 0.73 | FAAH (0.53) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20250257409-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTICS PRESCREENING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-08-14 | — | — | US | disclosed |
| US-12344899-B2 | Compositions and methods for therapeutics prescreening | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-07-01 | — | — | US | disclosed |
| CN-120022383-A | Nucleic acid medicine for mediating cell pyrosis and application thereof | 上海交通大学 | 2025-05-23 | — | — | CN | disclosed |
| CN-119732913-A | Lipid nanoparticle freeze-dried preparation and preparation method and application thereof | 荣灿生物医药技术(上海)有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-118319880-B | Lipid nanoparticle for targeted lung efficient delivery of nucleic acid, inhalation formulation and application | 荣灿生物医药技术(上海)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118255678-B | Ionizable lipid compound and application thereof | 荣灿生物医药技术(上海)有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20230364270-A1 | LIPOSOME-ASSISTED IMAGING OF VASCULAR INFLAMMATION | HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ (FI) | 2023-11-16 | — | — | US | disclosed |
| US-11788146-B2 | Methods for therapeutics prescreening in bodily fluids | BARCODE DIAGNOSTICS LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20160220710-A1 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-08-04 | — | — | US | disclosed |
| US-9339462-B2 | Lipid vesicle compositions and methods of use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2016024281-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTICS PRESCREENING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED. (IL) | 2016-02-18 | — | — | WO | disclosed |
| US-20160038415-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-02-11 | — | — | US | disclosed |
| US-20150272884-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-10-01 | — | — | US | disclosed |
| US-8951542-B2 | Lipid vesicle compositions and methods of use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140271827-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2547327-A2 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | Massachusetts Institute of Technology (US) | 2013-01-23 | — | — | EP | disclosed |
| CN-101805369-B | Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof | UNIV SOUTHEAST | 2012-10-03 | — | — | CN | disclosed |
| CN-101805369-A | Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof | UNIV SOUTHEAST | 2010-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271827-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, LIPA, SGMS2 | FAAH 889/4885CES1 949/4885CES2 1251/4885 |
| US-20150272884-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, LIPA, SGMS2 | FAAH 889/4885CES1 949/4885CES2 1251/4885 |
| US-20160220710-A1 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | MSR1, CD68, SLC11A2 | FAAH 1939/4885CES1 516/4885CES2 550/4885 |
| US-20160038415-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, ANXA5, CD63 | FAAH 1226/4885CES1 1462/4885CES2 1391/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | FAAH 1698/4885CES1 3436/4885CES2 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.